MWNA
BDTX icon

Marshall Wace North America’s Black Diamond Therapeutics BDTX Stock Holding History

Marshall Wace North America’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-67,853
Closed -$1.65M – 1460
2021
Q1 		$1.65M Sell
67,853
-113,155
-63% -$3.05M 0.01% 882
2020
Q4 		$5.8M Buy
+181,008
New +$5.95M 0.03% 511

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace North America's BDTX Position: Q2 2021 in Review

Marshall Wace North America sold out of Black Diamond Therapeutics (BDTX) in Q2 2021, closing a stake of 67,853 shares — an estimated $1.65M sold.

Marshall Wace North America first reported a position in BDTX in Q4 2020 and held it in 2 quarters. The position peaked at $5.8M in Q4 2020. 102 funds tracked by Wall St. Rank hold BDTX as of Q2 2021.

  • Marshall Wace North America reported no remaining Black Diamond Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 67,853 Black Diamond Therapeutics shares in Q2 2021, an estimated $1.65M.
  • Marshall Wace North America first reported a position in Black Diamond Therapeutics in Q4 2020 and held it in 2 quarters.
  • Marshall Wace North America's Black Diamond Therapeutics position peaked at $5.8M in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.